Quanterix

Our Texas round-up continues with Quanterix experts Sannette Hall, Senior Field Applications Scientist and Samuel Olson, PhD, Business Development Manager, recently visiting The University of North Texas Health Science Center at Fort Worth, where they have integrated the semi-automated SR-X? workflow into their custom liquid handler system. Known onsite as “The Unicorn”, this one-of-a-kind custom liquid handler system will help catch Alzheimer's disease earlier. Without a patient having to wait to see a specialist, it can run approximately 3.9 million tests per year on a specific blood sample versus manually running about 486,000 per year. Learn about the benefits of the SR-X? Biomarker Detection System: https://lnkd.in/e-8Na765 #biomarkers #neurology #alzheimersdisease

Will you be attending AD/PD? 2025 in Vienna, Austria from April 1–5, 2025? Be sure to add these posters and live presentations to your itinerary: https://lnkd.in/e7v9pp-f Our latest blog highlights where and when to go to learn about plasma and blood biomarkers' role in detecting, treating, and researching Alzheimer's and Parkinson's Disease with Quanterix and our Simoa? technology suite while you're at the event. #alzheimersdisease #parkinsonsdisease #ADPD2025

Recent research highlights blood-based biomarkers as a promising tool for early Parkinson’s disease detection. Our latest application note highlights how alpha-synuclein, NfL, and GFAP show potential in monitoring disease progression, proving that ultra-sensitive detection technologies are key to unlocking their full clinical value. Read our latest app note to learn more about the new advances in Parkinson’s Disease biomarkers: https://lnkd.in/ehBpvaeB #parkinsonsdisease #biomarkers #neurology

WRIB is around the corner and we're looking forward to meeting you in New Orleans! Workshop on Recent Issues in Bioanalysis unites global experts from pharma/biotech companies, CROs, and multiple regulatory agencies to discuss current topics of interest in bioanalysis. Date: April 7-11 Location: New Orleans, LA Be sure to visit Booth 06 to learn how our ultra-sensitive Simoa? technology is revolutionizing biomarker detection. We look forward to insightful discussions and connecting with you in New Orleans! #wrib #pharma #bioanalysis

Stroke is one of the leading causes of death and disability worldwide. Traditional stroke diagnosis relies on neuroimaging, but limitations in accessibility and sensitivity leave gaps in timely intervention. Our latest blog explores how blood-based biomarkers are emerging as a powerful tool for stroke research, diagnosis, and prognosis: https://lnkd.in/euaJJs5E Monitoring stroke biomarkers can aid not only in diagnosis but in predicting the potential for stroke recurrence, assessing treatment response and identifying patients that would benefit from specific interventions, such as neuroprotective therapies--making it invaluable for improving stroke care overall. #stroke #neurology #biomarkers

#News This study explores the changes in neurofilament light chain (NfL) concentrations in cerebrospinal fluid and serum in adult patients with 5q-associated spinal muscular atrophy (SMA) treated with nusinersen over a maximum of 60 months. NfL levels were significantly higher in SMA patients at baseline compared to controls. Over time, NfL concentrations decreased during each treatment phase, suggesting NfL's potential as a pharmacodynamic marker of response to nusinersen. These findings suggest that NfL could be a useful biomarker for tracking treatment effects in SMA. Read more: https://lnkd.in/e52K_f2a #neurology #neurofilamentlightchain #QReview

Quanterix experts Sannette Hall, Senior Field Applications Scientist and Samuel Olson, PhD, Business Development Manager, recently visited the UT Southwestern Medical Center to host a lunch and learn seminar on Simoa?--highlighting its ability to detect neurology and stroke biomarkers with exceptional sensitivity and precision. The session also demonstrated how the fully automated HD-X platform enhances high-throughput workflows with improved reproducibility and accuracy. Learn how Simoa is changing the way in which the biology of health and disease is studied here: https://lnkd.in/e_y8fWmZ #biomarkers #neurology

?? March is Multiple Sclerosis (MS) Awareness Month, and this week marks MS Awareness Week. MS is a chronic autoimmune disease affecting 1 in 3,000 people worldwide. Identifying high-risk patients early is critical for improving outcomes. Blood-based biomarkers like NfL and GFAP are transforming MS research by providing a non-invasive, rapid, and cost-effective way to assess neuroaxonal damage. Learn more in our blog on MS biomarkers and their role in detection and treatment: https://lnkd.in/eWUvHSEu #MSAwarenessMonth #MSAwarenessWeek #Simoa #Biomarkers

The Accelerator Lab is where our expertise drives innovation in research, drug discovery, biomarker testing, and pathology studies. Explore how our tailored solutions can meet the unique needs of your research and clinical programs. Whether you’re conducting exploratory studies or advancing therapeutic trials, our structured approach ensures the optimal level of validation and data integrity at every stage. Learn more: https://lnkd.in/eciK3vwu #pathology #acceleratorlab #biomarkers

At Quanterix, innovation isn’t just a buzzword—it’s at the heart of everything we do. From pioneering advancements in early disease detection to working together in a culture that values growth, every day is an opportunity to make a real impact. Hetal Shah, Senior Director, IT, Business Partner and PMO, is proud to be part of a team that’s changing the future of healthcare! ?? Learn more about open roles on Hetal's team here: https://lnkd.in/ek8yRgX5 #Innovation #Teamwork #CompanyCulture